Ypsomed undaunted by sanofi-aventis pen plans, projects +10% sales in '07
This article was originally published in Clinica
Executive Summary
Almost 45% growth in sales of its core pen systems and pen needles pushed Swiss drug delivery technology company Ypsomed (Burgdorf) to new heights in 2005-06.